Feasibility Study of Duloxetine in the Treatment of Depression in Patients With Traumatic Brain Injury
This study has been terminated.
(Most potential subjects had already been prescribed Cymbalta.)
Sponsor:
Rehabilitation Hospital of Indiana
Collaborator:
Eli Lilly and Company
Information provided by (Responsible Party):
Rehabilitation Hospital of Indiana
ClinicalTrials.gov Identifier:
NCT01223001
First received: October 15, 2010
Last updated: December 15, 2014
Last verified: November 2014
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
The primary objective of the study is to compare the efficacy of duloxetine 60 mg by mouth daily with placebo in the prevention of depression associated with mild/moderate traumatic brain injury and to enhance cognitive function.
| Condition | Intervention | Phase |
|---|---|---|
|
Traumatic Brain Injury Depression |
Drug: Duloxetine Drug: Sugar pill |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | Prevention of Depression and Enhancement of Cognitive Recovery Following Traumatic Brain Injury With Duloxetine |
Resource links provided by NLM:
Further study details as provided by Rehabilitation Hospital of Indiana:
Primary Outcome Measures:
- Hamilton Rating Scale for Depression [ Time Frame: 9 months ] [ Designated as safety issue: No ]To compare the efficacy of duloxetine 30 mg. PO daily to 120mg. PO daily with placebo in the prevention of depression associated with mild/moderate traumatic brain injury, utilizing the Hamilton Rating Scale for Depression (Hamilton, 1960; HAM-D) as the primary efficacy measure.
Secondary Outcome Measures:
- Hopkins Verbal Learning Test [ Time Frame: 9 months ] [ Designated as safety issue: No ]To compare the effect of duloxetine vs. placebo on the recovery of memory functions of patients with traumatic brain injury, utilizing the 20-minute delayed recall score of the Hopkins Verbal Learning Test (Brandt, 1991) as the secondary efficacy measure.
| Enrollment: | 8 |
| Study Start Date: | September 1996 |
| Study Completion Date: | July 2011 |
| Primary Completion Date: | July 2011 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: Duloxetine
Duloxetine 30 mg. PO daily to 120mg. PO daily for nine months in patients who have suffered a traumatic brain injury at least six months previously.
|
Drug: Duloxetine
Duloxetine 30 mg. PO daily to 120mg. PO daily for nine months in patients who have suffered a traumatic brain injury at least six months previously.
Other Name: Cymbalta
|
|
Placebo Comparator: Sugar pill
Sugar pills 30 mg. PO daily to 120mg. PO daily for nine months in patients who have suffered a traumatic brain injury at least six months previously.
|
Drug: Sugar pill
Sugar pills 30 mg. PO daily to 120mg. PO daily for nine months in patients who have suffered a traumatic brain injury at least six months previously.
Other Name: Lactose
|
Detailed Description:
The primary objective of the study is to compare the efficacy of duloxetine 60 mg by mouth daily with placebo in the prevention of depression associated with mild/moderate traumatic brain injury and to enhance cognitive function. Research exploring the use of selective serotonin reuptake inhibitors in the treatment of post-traumatic depression generally validates this approach (Horsfield et al., 2002). However, the literature suggests that serotonin/norepinephrine reuptake inhibitors such as duloxetine may be more effective in the treatment of depression.
Eligibility| Ages Eligible for Study: | 18 Years to 75 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Study participants will be 40 men and women between the ages of 18 and 75 who provide appropriate consent and who are agreeable to study requirements
- Diagnosed with mild to moderate traumatic brain injury as defined by an initial Mayo Traumatic Brain Injury Severity Scale
- Have memory impairments defined by a Hopkins Verbal Learning Test delayed recall score which falls less than or equal to 1.5 standard deviation below the mean.
Exclusion Criteria:
- Refusal to give informed consent
- A previous Central Nervous System illness or injury, including seizure that exhibits residual symptoms.
- Current post-traumatic seizure disorder
- A previous diagnosis of a psychotic disorder
- Current or previous (in the last 6 months) treatment history for alcohol or substance dependency
- Medications affecting noradrenergic or dopaminergic systems, alpha-adrenergic antihypertensives, antidepressant, phenobarbital, Monoamine oxidase inhibitor (MAOI), scheduled benzodiazepines, psychoactive herbal supplements (including Kava, St. John's wort), or nutritional supplements or within at least 14 days of discontinuing treatment with the above medications or supplements.
- A known suicide risk
- A pregnant or breastfeeding woman
- Uncontrolled narrow-angle glaucoma
- Serious and/or unstable medical comorbidity (e.g., AIDS, cancer, history of uncontrolled hypertension or cardiovascular disease) psychological condition, or clinically significant laboratory abnormality that in the opinion of the investigator would compromise participation in the study or be likely to lead to hospitalization during the course of the study
- Liver enzymes > 1.5 times upper limit of normal
- Patients with end-stage renal disease (requiring dialysis) or severe renal impairment
- Known hypersensitivity to duloxetine or any of the inactive ingredients
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01223001
Please refer to this study by its ClinicalTrials.gov identifier: NCT01223001
Locations
| United States, Indiana | |
| Rehabilitation Hospital of Indiana | |
| Indianapolis, Indiana, United States, 46254 | |
Sponsors and Collaborators
Rehabilitation Hospital of Indiana
Eli Lilly and Company
Investigators
| Principal Investigator: | Lance Trexler, Ph.D. | Rehabilitation Hospital of Indiana |
More Information
No publications provided
| Responsible Party: | Rehabilitation Hospital of Indiana |
| ClinicalTrials.gov Identifier: | NCT01223001 History of Changes |
| Other Study ID Numbers: | RHI 05-096, F1J-US-X025 |
| Study First Received: | October 15, 2010 |
| Results First Received: | November 6, 2014 |
| Last Updated: | December 15, 2014 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Rehabilitation Hospital of Indiana:
|
Depression Traumatic brain injury Duloxetine Cymbalta impaired cognitive function |
Additional relevant MeSH terms:
|
Brain Injuries Brain Diseases Craniocerebral Trauma Trauma, Nervous System Wounds and Injuries Depression Depressive Disorder Behavioral Symptoms Central Nervous System Diseases Mental Disorders Mood Disorders Nervous System Diseases Duloxetine Adrenergic Agents Adrenergic Uptake Inhibitors |
Analgesics Antidepressive Agents Central Nervous System Agents Dopamine Agents Dopamine Uptake Inhibitors Molecular Mechanisms of Pharmacological Action Neurotransmitter Agents Neurotransmitter Uptake Inhibitors Peripheral Nervous System Agents Pharmacologic Actions Physiological Effects of Drugs Psychotropic Drugs Sensory System Agents Serotonin Agents Serotonin Uptake Inhibitors |
ClinicalTrials.gov processed this record on March 01, 2015